crizanlizumab-tmca

crizanlizumab-tmca (ADAKVEO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

ADAKVEO is a marketed brand name for crizanlizumab-tmca. Check FDA Drugs@FDA for the current US label holder and prescribing information.

crizanlizumab-tmca has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.